biostudies-literatureUnknown13Reyburn R<h4>Background</h4>There is an ongoing need to assess the impact of pneumococcal conjugate vaccines (PCVs) to guide the use of these potentially valuable but under-utilized vaccines against pneumonia, which is one of the most common causes of post-neonatal mortality.<h4>Methods</h4>We conducted a systematic review of the literature on PCV10 and PCV13 impact on all-cause, radiologically confirmed and severe pneumonia hospitalisation rates as well as all-cause and pneumonia-specific mortality rates. We included studies that were published from 2003 onwards, had a post-licensure observational study design, and reported on any of our defined outcomes in children aged between 0-9 years. We derived incidence rates (IRs), incidence rate ratios (IRRs) or percent differences (%). We assessed all stJournal of global health05002https://www.ebi.ac.uk/biostudies/studies/S-EPMC9896304biostudies-literatureSystematic review on the impact of the pneumococcal conjugate vaccine ten valent (PCV10) or thirteen valent (PCV13) on all-cause, radiologically confirmed and severe pneumonia hospitalisation rates and pneumonia mortality in children 0-9 years old.PMC9896304von Mollendorf CChua PTsatsaronis ASimon JWilkes CDuke TKazi SMulholland KGraham HWere WKevat PQuach AWalker PRussell FARI Review groupNeal EReyburn RNisar YBNguyen CGwee AGraham SRussell FMGray AHume-Nixon MRyan KfalseSystematic review on the impact of the pneumococcal conjugate vaccine ten valent (PCV10) or thirteen valent (PCV13) on all-cause, radiologically confirmed and severe pneumonia hospitalisation rates and pneumonia mortality in children 0-9 years old.<h4>Background</h4>There is an ongoing need to assess the impact of pneumococcal conjugate vaccines (PCVs) to guide the use of these potentially valuable but under-utilized vaccines against pneumonia, which is one of the most common causes of post-neonatal mortality.<h4>Methods</h4>We conducted a systematic review of the literature on PCV10 and PCV13 impact on all-cause, radiologically confirmed and severe pneumonia hospitalisation rates as well as all-cause and pneumonia-specific mortality rates. We included studies that were published from 2003 onwards, had a post-licensure observational study design, and reported on any of our defined outcomes in children aged between 0-9 years. We derived incidence rates (IRs), incidence rate ratios (IRRs) or percent differences (%). We assessed all st2023-01-01T00:00:00Z2023 Feb2025-04-04T13:08:12.886Z2025-04-04T13:08:12.886ZS-EPMC98963043673419210.7189/jogh.13.05002